Total plasma homocysteine is associated with hypertension in Type I diabetic patients

Diabetologia

Volumn 45, Issue 9, 2002, Pages 1315-1324

  Neugebauer, S ^a   Tarnow, L ^b   Stehouwer, C ^c,d   Teerlink, T ^c   Baba, T ^a   Watanabe, T ^a   Parving, H H ^b  

^a FUKUSHIMA MEDICAL UNIVERSITY   (Japan)

^b STENO DIABETES CENTER   (Denmark)

^c VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^d VU UNIVERSITY AMSTERDAM   (Netherlands)

Author keywords

Gene polymorphism; Homocysteine; Hypertension; Methylenetetrahydrofolate reductase; Type I diabetes; Vascular complications

Indexed keywords

5,10 METHYLENETETRAHYDROFOLATE REDUCTASE (FADH2); HOMOCYSTEINE;

ADULT; ALLELE; ARTICLE; BLOOD LEVEL; BLOOD PRESSURE; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CONTROLLED STUDY; DIABETIC NEPHROPATHY; DISEASE ASSOCIATION; DNA POLYMORPHISM; FEMALE; GENOTYPE; GLOMERULUS FILTRATION RATE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HYPERHOMOCYSTEINEMIA; HYPERTENSION; INSULIN DEPENDENT DIABETES MELLITUS; ISCHEMIC HEART DISEASE; KIDNEY FUNCTION; MAJOR CLINICAL STUDY; MALE; MICROANGIOPATHY; PRIORITY JOURNAL; RISK FACTOR; VASCULAR DISEASE;

ADULT; ALBUMINURIA; BODY MASS INDEX; DIABETES MELLITUS, TYPE 1; DIABETIC ANGIOPATHIES; DIABETIC NEPHROPATHIES; FEMALE; GENOTYPE; GLOMERULAR FILTRATION RATE; HOMOCYSTEINE; HUMANS; HYPERTENSION; MALE; METHYLENETETRAHYDROFOLATE REDUCTASE (NADPH2); OXIDOREDUCTASES ACTING ON CH-NH GROUP DONORS; POLYMORPHISM, GENETIC; POLYMORPHISM, RESTRICTION FRAGMENT LENGTH; RISK FACTORS;

EID: 0036381990     PISSN: 0012186X     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00125-002-0908-4     Document Type: Article

References (38)

1. Borch-Johnsen K, Kreiner S, Deckert T (1986) Mortality of Type I (insulin-dependent) diabetes mellitus in Denmark. Diabetologia 29: 767-772
2. Borch-Johnsen K, Norgaard K, Hommel E et al. (1992) Is diabetic nephropathy an inherited disease? Kidney Int 41: 719-722
3. Quinn M, Angelico MC, Warram JH, Krolewski AS (1996) Familial factors determine the development of diabetic nephropathy in patients with IDDM. Diabetologia 39: 940-945
4. McCully KS (1996) Homocysteine and vascular disease. The discovery of hyperhomocysteinaemia as a major factor in the pathogenesis of arteriosclerosis offers new strategies and opportunities for prevention and treatment. Nat Med 4: 386-389
5. Frosst P, Blom HJ, Milos R (1995) A candidate genetic risk factor for vascular disease: a common mutation in methylenetetrahydrofolate reductase. Nat Genet 10: 111-113
6. Neugebauer S, Baba T, Watanabe T (1997) Defective homocysteine metabolism as a risk factor for diabetic retinopathy. Lancet 349: 473-474
7. Vaccaro O, Perna AF, Mancini FP et al. (2000) Plasma homocysteine and its determinants in diabetic retinopathy. Diabetes Care 23: 1026-1027
8. Neugebauer S, Baba T, Watanabe T (1998) Methylenetetrahydrofolate reductase gene polymorphism as a risk factor for diabetic nephropathy in NIDDM patients. Lancet 352: 454
9. Noiri E, Taguchi JI, Nakao A, Fujita T (2000) MTHFR gene polymorphism as an exacerbation factor of diabetic nephropathy in Type 2 diabetes: analysis in Japanese male hemodialysis patients. Diabetes Care 23: 260
10. Hultberg B, Agardh E, Andersson A et al. (1991) Increased levels of plasma homocysteine are associated with nephropathy, but not severe retinopathy in type 1 diabetes mellitus. Scand J Clin Lab Invest 51: 277-282
11. Hofmann MA, Kohl B, Zumbach MS et al. (1998) Hyperhomocysteinemia and endothelial dysfunction in IDDM. Diabetes Care 21: 841-848
12. Hoogeveen EK, Kostense PJ, Eysink PED et al. (2000) Hyperhomocysteinemia is associated with the presence of retinopathy in type 2 diabetes mellitus: the Hoorn study. Arch Intern Med 160: 2984-2990
13. Hoogeveen EK, KostensePJ, Mackaay AJ et al. (1998) Hyperhomocysteinemia is associated with an increased risk of cardiovascular disease, especially in non-insulin-dependent diabetes mellitus: a population-based study. Arterioscler Thromb Vasc Biol 18: 133-138
14. Mendis S, Athauda SB, Naser M, Takahashi K (1999) Association of hyperhomocysteinemia and hypertension in Sri Lankans. J Int Med Res 27: 38-44
15. Araki A, Sako Y, Fukushima Y, Matsumoto M, Asada T, Kita T (1989) Plasma sulfhydryl-containing amino acids in patients with cerebral infarction and in hypertensive subjects. Atherosclerosis 79: 139-146
16. Fiorina P, Lanfredini M, Montanari A, et al. (1998) Plasma homocysteine and folate are related to arterial blood pressure in Type 2 diabetes mellitus. Am J Hypertens 11: 1100-1107
17. Wollesen F, Brattström L, Refsum H, Ueland PM, Berglund L, Berne C (1999) Plasma total homocysteine and cysteine in relation to glomerular filtration rate in diabetes mellitus. Kidney Int 55: 1028-1035
18. Tarnow L, Cambien F, Rossing P et al. (1995) Lack of relationship between an insertion/deletion polymorphism in the angiotensin I-converting enzyme gene and diabetic nephropathy and proliferative retinopathy in IDDM patients. Diabetes 44: 489-494
19. Tarnow L, Cambien F, Rossing P et al. (1995) Insertion/deletion polymorphism in the angiotensin I-converting enzyme gene is associated with coronary heart disease in IDDM patients with diabetic nephropathy. Diabetologia 38: 798-803
20. Ueland PPM, Refsum H, Stabler SP, Malinow MR, Andersson A, Allen RH (1993) Total homocysteine in plasma or serum: methods and clinical applications. Clin Chem 39: 1764-1779
21. Savage DG, Lindenbaum J, Stabler SP, Allen RH (1994) Sensitivity of serum methylmalonic acid and total homocysteine determinations for diagnosing cobalamin and folate deficiencies. Am J Med 96: 239-246
22. Finkerstrand T, Refsum H, Kvalheim G, Ueland PM (1993) Homocysteine and other thiols in plasma and urine: automated determination and sample stability. Clin Chem 39: 263-271
23. Rossing P, Astrup AS, Smidt UM, Parving HH (1994) Monitoring kidney function in diabetic nephropathy. Diabetologia 37: 708-712
24. Sutton-Tyrrell K, Bostom A, Selhub J, Ziegler-Johnson C (1997) High homocysteine levels are independently related to isolated systolic hypertension in older adults. Circulation 96: 1745-1749
25. Nygard O, Vollset SE, Refsum H et al. (1995) Total plasma homocysteine and cardiovascular risk profile. The Hordaland Homocysteine Study. JAMA 274: 1526-1533
26. Bates CJ, Mansoor MA, Pols J van der, Prentice A, Cole TJ, Finch S (1997) Plasma homocysteine in a representative sample of 972 British men and women aged 65 and over. Eur J Clin Nutr 51: 691-697
27. Graham IM, Daly LE, Refsum HM et al. (1997) Plasma homocysteine as a risk factor for vascular disease. The European Concerted Action Project. JAMA 277: 1775-1781
28. Stampfer MJ (1992) Prospective study of plasma homocyst(e)ine and risk of myocardial infarction in US physicians. JAMA 268: 877-881
29. Stamler JS, Slivka A (1996) Biological chemistry of thiols in the vasculature and in vascular-related disease. Nutr Rev 54: 1-30
30. Mutus B, Rabini RA, Staffolani R et al. (2001) Homocysteine-induced inhibition of nitric oxide production in platelets: a study on healthy and diabetic subjects. Diabetologia 44: 979-982
31. Starkebaum G, Harlan JM (1986) Endothelial cell injury due to copper catalyzed hydroxide-peroxide generation from homocysteine. J Clin Invest 77: 1370-1376
32. Schachinger V, Britten MB, Elsner M, Walter DH, Scharrer I, Zeiher AM (1999) A positive family history of premature coronary artery disease is associated with impaired endothelium-dependent coronary blood flow regulation. Circulation 100: 1502-1508
33. Bortolotto LA, Safar ME, Billaud E et al. (1999) Plasma homocysteine, aortic stiffness and renal function in hypertensive patients. Hypertension 34: 837-842
34. Bostom A, Brosnan JT, Hall B, Nadeau MR, Selhub J (1995) Net uptake of plasma homocysteine by the rat kidney in vivo. Atherosclerosis 116: 59-62
35. Smulders YM, Rakic M, Slaats EH et al. (1999) Fasting and post-methionine homocysteine levels in NIDDM: determinants and correlations with retinopathy, albuminuria, and cardiovascular disease. Diabetes Care 22: 125-132
36. Davies L, Wilmshurst EG, McElduff A, Gunton J, Clifton-Bligh P, FulcherGR (2001) The relationship among homocysteine creatinine clearance, and albuminuria in patients with type 2 diabetes. Diabetes Care 24: 1805-1809
37. Stehouwer CDA, Gall MA, Hougaard P, Jakobs C, Parving HH (1999) Plasma homocysteine concentration predicts mortality in non-insulin-dependent diabetic patients with and without albuminuria. Kidney Int 55: 308-314
38. Bostom AG, Shemin D, Lapane KL et al. (1996) Folate status is the major determinant of fasting total plasma homocysteine levels in maintenance dialysis patients. Atherosclerosis 123: 193-202